Enlivex reports $1.23B profit in 2025 as shares surge 9% on NASDAQ

Enlivex Ltd. has released its financial results for fiscal year 2025, revealing a net profit of $1.23 billion. The company's earnings per share (EPS) soared to $25.48, triggering a 9.09% jump in its NASDAQ share price shortly after the announcement on March 24, 2026. As of early March, shares traded between $1.02 and $1.16, with a market capitalisation of around $273 million. The biotechnology firm combines a clinical-stage immunotherapy platform with a unique treasury model. This dual-engine strategy, as described by Executive Chairman Shai Novik, aims to fund longevity research while leveraging the Rain decentralised prediction markets protocol. By the end of 2025, Enlivex held $2.31 billion in treasury and related derivative assets, alongside $30 million in cash, equivalents, and short-term digital investments.

The company's total shareholders' equity reached approximately $1.93 billion. Its core focus remains on advancing Allocetra™, an immunotherapy designed to combat inflammatory conditions tied to ageing. The treatment primarily targets age-related osteoarthritis, positioning Enlivex at the forefront of quality longevity therapeutics. Enlivex's financial performance in 2025 highlights both its profitability and innovative funding approach. With substantial treasury reserves and a rising share price, the company continues to push forward in biotech research. The dual-engine model sets a new precedent for financing longevity-focused medical advancements.